Novartis Reports Evidence Gilenya Reduce MS Relapse Rates More Effectively than Interferons or Glatiramer Acetate

Novartis (NYSE: NVS ) announced today findings from an international multiple sclerosis (MS) registry and a US health claims data base which showed the real-world superiority of Gilenya® (fingolimod) in reducing risks of relapses compared to standard therapies[1]-[3]. These data confirm the positive results seen in clinical trials with